A Genetic Case of Limited Resources: Sickle Cell Trial Cancelled, Layoffs at Graphic Bio
"CIRM-catalyzed" firm hits a rocky spot
A company once celebrated by the $12 billion California stem cell agency canceled its gene therapy clinical trial for sickle disease this week and is laying off 50 percent of its staff.
The moves by the publicly traded firm highlight the financial and scientific difficulties in producing what often are called “one-and-done” cures.
The company is Graphi…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.